Purchase this article with an account.
B. Fiore, K. Haas, N. Feucht, C. Winkler von Mohrenfels, I. Lanzl, A. Clos, C. P. Lohmann, M. Maier; Intravitreal Injection of Bevacizumab for Exsudative AMD With Occult or Minimal Classic Choroidal Neovascularisation (CNV). Invest. Ophthalmol. Vis. Sci. 2007;48(13):4541.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Systemic Anti-VEGF therapy with Bevacizumab was effective in neovascular AMD in the SANA-study. Intravitreal Bevacizumab has the advantage that with a low dose a high concentration can be achieved in the eye. First clinical reports showed a therapeutic effect.
In a clinical study 100 Patients with occult or minimal classic CNV due to neovascular AMD were treated every 8 weeks with intravitreal injection of Bevacizumab. Before, 1, 3 and 6 months after treatment visual acuity, intraocular pressure measurement, angiography and OCT examination were performed. One day and after one week an eye examination was done and the intraocular pressure was measured.
Bevacizumab was well tolerated and we had no complications. Mean visual acuity was improved significantly from 20/200 at baseline to 20/80 after one month. At month 3 and 6 from baseline mean VA was 20/200 and was stabilized compared to baseline. In all patients in fluorescein angiography and on OCT, leakage and retinal thickness were reduced. (OCT: mean 337µm at baseline, 264µm after 1, 295µm after 3 and 304 after 6 months)
Intravitreal therapy with Bevacizumab was safe and well tolerated. It is a therapeutic option in treating occult choroidal neovascularisations and minimal classic CNV. One month after intravitreal application of Bevacizumab mean visual acuity was better and retinal thickness and leakage was more reduced than after 3 and 6 months. According to our results a monthly injection schedule could give more favorable results.
This PDF is available to Subscribers Only